 Antitubercular Agents
"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 | | 2002 | 3 | 1 | 4 | | 2003 | 5 | 0 | 5 | | 2004 | 3 | 1 | 4 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 2 | 0 | 2 | | 2010 | 4 | 1 | 5 | | 2011 | 7 | 4 | 11 | | 2012 | 6 | 4 | 10 | | 2013 | 4 | 0 | 4 | | 2014 | 5 | 3 | 8 | | 2015 | 2 | 1 | 3 | | 2016 | 5 | 5 | 10 | | 2017 | 3 | 0 | 3 | | 2018 | 10 | 4 | 14 | | 2019 | 7 | 2 | 9 | | 2020 | 3 | 3 | 6 | | 2021 | 3 | 5 | 8 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Reichlen MJ, Born SEM, Lyons MA, Rossmassler K, Reid J, Robertson GT, Walter ND, Voskuil MI. Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0148322.
-
Campbell JR, Chan ED, Falzon D, Trajman A, Keshavjee S, Leung CC, Miller AC, Monedero-Recuero I, Rodrigues DS, Seo H, Baghaei P, Udwadia Z, Viiklepp P, Bastos M, Menzies D. Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 12 19; 75(12):2201-2210.
-
Dide-Agossou C, Bauman AA, Ramey ME, Rossmassler K, Al Mubarak R, Pauly S, Voskuil MI, Garcia-Cremades M, Savic RM, Nahid P, Moore CM, Tasneen R, Nuermberger EL, Robertson GT, Walter ND. Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments. Antimicrob Agents Chemother. 2022 04 19; 66(4):e0231021.
-
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875.
-
Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467.
-
Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0170521.
-
Gonzalez-Juarrero M, Lukka PB, Wagh S, Walz A, Arab J, Pearce C, Ali Z, Ryman JT, Parmar K, Temrikar Z, Munoz-Gutierrez J, Robertson GT, Liu J, Lenaerts AJ, Daley C, Lee RE, Braunstein M, Hickey AJ, Meibohm B. Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infect Dis. 2021 10 08; 7(10):2850-2863.
-
Davidson RM, Benoit JB, Kammlade SM, Hasan NA, Epperson LE, Smith T, Vasireddy S, Brown-Elliott BA, Nick JA, Olivier KN, Zelazny AM, Daley CL, Strong M, Wallace RJ. Genomic characterization of sporadic isolates of the dominant clone of Mycobacterium abscessus subspecies massiliense. Sci Rep. 2021 07 28; 11(1):15336.
-
Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Martiniano SL, Wagner BD, Brennan L, Wempe MF, Anderson PL, Daley CL, Anthony M, Nick JA, Sagel SD. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. J Cyst Fibros. 2021 09; 20(5):772-778.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|